Sava
Generated by Meeveem AI
"Developing wearable biosensors for continuous molecular health monitoring"
About Sava
Sava develops minimally invasive wearable biosensors for continuous molecular monitoring just below the skin, with glucose as its first application. Its platform is designed for low-cost manufacturing and phone-connected health data. Longer-term plans cover lactate, ketones, sodium, histamine, cortisol, alcohol and urea; these are development ambitions rather than established clinical capabilities.
Founded in 2019 by Imperial College London bioengineers Renato Circi and Rafaël Michali, the London company is working towards preventative and personalised healthcare. A 46-participant diabetes study reported glucose monitoring over ten days. The device remains experimental; an October 2026 update targets commercialisation within 18 to 24 months, subject to approval.
From research to manufacture
Sava's work spans biosensor development, clinical validation and manufacturing. Its published growth plans include expanding a team with experience in established continuous glucose monitors and advancing automated manufacturing capacity. The company is preparing further clinical studies and regulatory submissions alongside this work.
Preparing for European distribution
In October 2026 Sava announced a $36 million Series B and appointed Ascensia as its commercialisation and distribution partner, initially in Europe. Ascensia is to lead launch subject to CE approval, while Sava scales manufacturing and prepares clinical evidence.
35
Team Members
2019
Founded
Medical Devices
Sector
Hybrid
Work Environment